Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Recommendation of “Hold” by Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have earned an average recommendation of “Hold” from the seven brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $56.40.

Several research analysts have recently weighed in on PSTV shares. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Tuesday, April 21st. Wall Street Zen upgraded Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Ascendiant Capital Markets lowered their target price on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Finally, D. Boral Capital restated a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st.

Plus Therapeutics Stock Performance

PSTV stock opened at $4.20 on Friday. Plus Therapeutics has a 12-month low of $2.90 and a 12-month high of $23.42. The stock has a market cap of $28.90 million, a price-to-earnings ratio of -1.83 and a beta of 1.38. The business’s 50-day moving average is $5.81 and its 200 day moving average is $8.02.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.20). Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.97 million. As a group, equities analysts forecast that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of Plus Therapeutics during the 4th quarter valued at approximately $254,000. XTX Topco Ltd purchased a new stake in shares of Plus Therapeutics during the 4th quarter valued at approximately $127,000. State Street Corp raised its position in shares of Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after buying an additional 127,000 shares during the period. L1 Global Manager Pty Ltd purchased a new stake in shares of Plus Therapeutics during the 4th quarter valued at approximately $1,167,000. Finally, Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics during the 4th quarter valued at approximately $525,000. 3.28% of the stock is currently owned by institutional investors and hedge funds.

About Plus Therapeutics

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.